bearish
BeiGene (6160.HK/BGNE.US) 23H1 - "Accidents" Behind the Strong Growth
351 Views08 Aug 2023 08:55
BeiGene's financial performance starts to become healthier in 23H1. As BeiGene approaches breakeven, it's particularly crucial to avoid "accidents" that could affect the sustained high growth momentum
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Sep.1) - China's New IPO Reform, Financing Environment, Junshi Biosciences03 Sep 2023
- What Will BRICS Bring to the World? - The Rise of The Rest30 Aug 2023
- Pre-IPO Sunho Biologics (SHB HK) - High Valuations Can Be Hard to Come By24 Aug 2023
- WuXi AppTec (2359.HK/603259.CH) 23H1 - Is It Time to Start Being Optimistic?03 Aug 2023
- BeiGene (6160.HK/BGNE.US) - Novartis Chose to Escape Before Tragedy of TIGIT Truly Comes12 Jul 2023
- BeiGene (6160.HK/BGNE.US) - AbbVie‘s Patent Infringement Allegations Are Not as Simple as Imagined19 Jun 2023
x